Amgen reports more Phase 3 Uplizna data in myasthenia gravis ahead of FDA filing
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s case for label expansion before a planned FDA filing this quarter. The...
View ArticleMontara Therapeutics adds $20M to seed fundraise for neurology pipeline
Montara Therapeutics has raised $20 million in an expanded seed financing to advance a pipeline of preclinical CNS candidates that it says could address safety concerns that have hampered R&D...
View ArticleGoodRx CEO Wendy Barnes on the future of the drug discount company
GoodRx has been in a rut. In its almost five years as a public company, its revenue flatlined, and its stock price plunged about 90%. Its founders stepped down as co-CEOs in 2023, and temporary ...
View ArticleEndpoints wins SABEW award for Health Tech coverage
When Endpoints News launched our Health Tech newsletter in Fall 2023, it was the first time our newsroom had stepped outside the world of biopharma. It was a bet that our readers, and future...
View ArticleInside Pepper, a New York health tech professional community
Tucked away in a corner of a hip Midtown Manhattan taproom, a group huddled over draft beers on Valentine's Day was smitten — not with each other, but with health tech. On one end of the ...
View ArticleUpdated: White House pulls Weldon's nomination to lead CDC
The White House pulled the nomination of its proposed CDC Director Dave Weldon just hours before a Senate confirmation hearing was scheduled to begin, a surprise failure in what has been a relatively...
View ArticleCanada pitches in to Entos' facility build; Vetter expands in Germany
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. The Government of Canada is contributing $62 million to Entos...
View ArticleAcelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both...
Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning. Acelyrin, a struggling...
View ArticleWith Hinge Health filing to go public, are we... back?
When Hinge Health filed to go public on Monday afternoon, I’ll admit I was caught off guard. In part, because the stock market had its worst day of the year. But ...
View ArticleMeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene...
A small-cap biotech developing gene therapies is spinning out its Parkinson’s disease program into a new company in partnership with a secretive AI startup co-founded by former Google CEO Eric Schmidt....
View ArticlePfizer terminates an early-stage STING agonist trial
Pfizer's pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a spokesperson confirmed to Endpoints News. The company ended a Phase 1 trial of...
View ArticleMoonLake's CEO on its looming mid-year pivotal readout in skin disease
MIAMI — MoonLake Immunotherapeutics is expected to have one of the biotech industry's biggest stock-moving clinical readouts around the middle of this year for a pair of Phase 3 trials in a painful...
View ArticleLilly-partnered Fauna Bio plans $40M Series A to get into heart failure
MIAMI — Fauna Bio, a biotech that mines data on disease resistance from squirrels and other animals to create new drugs, is looking at raising a Series A to get its first program into clinical trials ...
View ArticleMerck diversity leader to retire this summer; Geron seeks commercial chops...
→ Celeste Warren said in a LinkedIn post that she is retiring from Merck on July 7. Warren joined Merck in 1997 and has been VP of the company’s Global Diversity ...
View ArticleSutro slashes workforce in half, changes CEO and closes factory
Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away from its lead candidate. The major reshuffle is intended to save cash, which...
View ArticleAltimmune to put its incretin into addiction trials; Tarsus aims to raise $125M
Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction: Following the path set by Novo Nordisk last week, Altimmune said...
View ArticleRFK Jr. convened roundtable around ways to reduce stem cell regulation
HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to discuss how to lower regulatory barriers for stem cell treatments, three people...
View ArticleRecipharm hits record revenue, eyes GLP-1 deals for growth
Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO. The CDMO reported record-high revenues on Friday, and the company expects it will be able to tap into the booming GLP ...
View ArticleUK’s drugmaker rebate plan draws scrutiny from industry
The UK government is planning to double the proportion of money drugmakers have to pay back on medicine sales to the National Health Service in a move that’s drawn backlash from industry. In the UK ...
View ArticleBoston Pharma mulls IPO amid MASH momentum
The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And another late-stage startup is gaining traction. Boston Pharmaceuticals,...
View Article